Advertisement
UK markets close in 27 minutes
  • FTSE 100

    8,036.96
    +13.09 (+0.16%)
     
  • FTSE 250

    19,757.39
    +158.00 (+0.81%)
     
  • AIM

    755.09
    +5.91 (+0.79%)
     
  • GBP/EUR

    1.1621
    +0.0032 (+0.27%)
     
  • GBP/USD

    1.2429
    +0.0079 (+0.64%)
     
  • Bitcoin GBP

    53,758.34
    +594.13 (+1.12%)
     
  • CMC Crypto 200

    1,436.12
    +21.36 (+1.51%)
     
  • S&P 500

    5,058.20
    +47.60 (+0.95%)
     
  • DOW

    38,439.01
    +199.03 (+0.52%)
     
  • CRUDE OIL

    82.26
    +0.36 (+0.44%)
     
  • GOLD FUTURES

    2,332.90
    -13.50 (-0.58%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     
  • DAX

    18,100.07
    +239.27 (+1.34%)
     
  • CAC 40

    8,094.99
    +54.63 (+0.68%)
     

What Is Orexo's (STO:ORX) P/E Ratio After Its Share Price Rocketed?

Orexo (STO:ORX) shareholders are no doubt pleased to see that the share price has had a great month, posting a 38% gain, recovering from prior weakness. Unfortunately, the full year gain of 9.6% wasn't so sweet.

Assuming no other changes, a sharply higher share price makes a stock less attractive to potential buyers. In the long term, share prices tend to follow earnings per share, but in the short term prices bounce around in response to short term factors (which are not always obvious). So some would prefer to hold off buying when there is a lot of optimism towards a stock. Perhaps the simplest way to get a read on investors' expectations of a business is to look at its Price to Earnings Ratio (PE Ratio). Investors have optimistic expectations of companies with higher P/E ratios, compared to companies with lower P/E ratios.

View our latest analysis for Orexo

Does Orexo Have A Relatively High Or Low P/E For Its Industry?

We can tell from its P/E ratio of 9.52 that sentiment around Orexo isn't particularly high. We can see in the image below that the average P/E (22.9) for companies in the pharmaceuticals industry is higher than Orexo's P/E.

OM:ORX Price Estimation Relative to Market May 12th 2020
OM:ORX Price Estimation Relative to Market May 12th 2020

Orexo's P/E tells us that market participants think it will not fare as well as its peers in the same industry. While current expectations are low, the stock could be undervalued if the situation is better than the market assumes. It is arguably worth checking if insiders are buying shares, because that might imply they believe the stock is undervalued.

How Growth Rates Impact P/E Ratios

Generally speaking the rate of earnings growth has a profound impact on a company's P/E multiple. That's because companies that grow earnings per share quickly will rapidly increase the 'E' in the equation. That means unless the share price increases, the P/E will reduce in a few years. So while a stock may look expensive based on past earnings, it could be cheap based on future earnings.

ADVERTISEMENT

In the last year, Orexo grew EPS like Taylor Swift grew her fan base back in 2010; the 61% gain was both fast and well deserved. And earnings per share have improved by 115% annually, over the last three years. So you might say it really deserves to have an above-average P/E ratio.

Remember: P/E Ratios Don't Consider The Balance Sheet

Don't forget that the P/E ratio considers market capitalization. In other words, it does not consider any debt or cash that the company may have on the balance sheet. In theory, a company can lower its future P/E ratio by using cash or debt to invest in growth.

Such expenditure might be good or bad, in the long term, but the point here is that the balance sheet is not reflected by this ratio.

Is Debt Impacting Orexo's P/E?

Orexo has net cash of kr612m. This is fairly high at 22% of its market capitalization. That might mean balance sheet strength is important to the business, but should also help push the P/E a bit higher than it would otherwise be.

The Verdict On Orexo's P/E Ratio

Orexo trades on a P/E ratio of 9.5, which is below the SE market average of 16.8. Not only should the net cash position reduce risk, but the recent growth has been impressive. The relatively low P/E ratio implies the market is pessimistic. What we know for sure is that investors are becoming less uncomfortable about Orexo's prospects, since they have pushed its P/E ratio from 6.9 to 9.5 over the last month. For those who like to invest in turnarounds, that might mean it's time to put the stock on a watchlist, or research it. But others might consider the opportunity to have passed.

Investors should be looking to buy stocks that the market is wrong about. If it is underestimating a company, investors can make money by buying and holding the shares until the market corrects itself. So this free visualization of the analyst consensus on future earnings could help you make the right decision about whether to buy, sell, or hold.

But note: Orexo may not be the best stock to buy. So take a peek at this free list of interesting companies with strong recent earnings growth (and a P/E ratio below 20).

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.